Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQ: AMLX · Real-Time Price · USD
5.23
+0.01 (0.19%)
At close: Nov 20, 2024, 4:00 PM
5.31
+0.08 (1.53%)
Pre-market: Nov 21, 2024, 4:04 AM EST
Amylyx Pharmaceuticals Employees
Amylyx Pharmaceuticals had 384 employees as of December 31, 2023. The number of employees increased by 122 or 46.56% compared to the previous year.
Employees
384
Change (1Y)
122
Growth (1Y)
46.56%
Revenue / Employee
$511,680
Profits / Employee
-$675,693
Market Cap
356.07M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 384 | 122 | 46.56% |
Dec 31, 2022 | 262 | 57 | 27.80% |
Dec 31, 2021 | 205 | 171 | 502.94% |
Dec 31, 2020 | 34 | - | - |
Related Stocks
Company Name | Employees |
---|---|
ZimVie | 2,600 |
Valneva SE | 676 |
AirSculpt Technologies | 381 |
Akebia Therapeutics | 167 |
ProQR Therapeutics | 157 |
4D Molecular Therapeutics | 147 |
Larimar Therapeutics | 42 |
Q32 Bio | 37 |
AMLX News
- 2 days ago - Best Cheap Stocks To Buy Now (Under $10) - Kiplinger
- 11 days ago - Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 13 days ago - Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results - Business Wire
- 16 days ago - Amylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024 - Business Wire
- 4 weeks ago - Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome - Business Wire
- 5 weeks ago - Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024 - Business Wire
- 6 weeks ago - Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm - PRNewsWire
- 3 months ago - Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences - Business Wire